Code Biotherapeutics, Inc.

Takeda Pharmaceutical Co. Ltd. has discontinued preclinical R&D work in the area of adeno-associated virus (AAV) gene therapies, as well as research and preclinical efforts in rare hematology. The de

As 2022 proves to be a year of missed predictions and uncertainty, we are using this year's BIO notebook to provide additional context by reviewing different industry metrics to provide more perspecti

The State Of Business Development Big pharma and specialty pharmaceutical companies have made it clear that they are hunting for new technologies and drug candidates to expand their R&D pipelines in a

As 2022 proves to be a year of missed predictions and uncertainty, we are using this year's BIO notebook to provide additional context by reviewing different industry metrics to provide more perspecti